A Demonstration of the Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion as Compared to 0.05% Clobetasol Propionate Cream in the Treatment of Psoriasis

The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.

开始日期2023-07-13

申办/合作机构-

NCT05608499

/ Terminated临床3期IIT

Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN)

Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoid combination approved by the FDA with dermatologic indication. Researchers are proposing the off-labeled use of Duobrii for the management of early-mild AKN. The research team hypothesizes that subjects will experience significant clinical improvement in lesion counts. Patients will be followed with visits scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. During these in-clinic visits, there will be surveys regarding the severity of AKN symptoms, photographs, and clinical assessments.

开始日期2022-10-26

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+1]

NCT04571151

/ Unknown status临床4期

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis After Combination Treatment of Lexette and Sorilux for 2 Weeks

The study seeks to show whether there is additional benefit of using Lexette and Sorilux in the beginning of the treatment, and then maintenance treatment of Sorilux alone in moderate plaque type psoriasis patients.

开始日期2021-01-01

申办/合作机构

Skin Sciences, Inc.

100 项与丙酸乌倍他索相关的临床结果

登录后查看更多信息

100 项与丙酸乌倍他索相关的转化医学

登录后查看更多信息

100 项与丙酸乌倍他索相关的专利（医药）

登录后查看更多信息

138

项与丙酸乌倍他索相关的文献（医药）

2025-08-01·Journal of Drugs in Dermatology

Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene

Review

作者: Draelos, Zoe D. ; Green, Lawrence ; Tanghetti, Emil A. ; Jacobson, Abby ; Lebwohl, Mark G. ; Gold, Linda Stein

BACKGROUND:

Hyperkeratotic plaque psoriasis represents a distinct morphological variant that is difficult to treat with topical therapies because thick lesions may impede the penetration of active ingredients. The immunoregulatory mechanisms of topical corticosteroids (TCSs) and tazarotene (TAZ) may contribute to combating hyperkeratosis and long-term remittance of psoriasis. A fixed-combination lotion containing the potent-to-superpotent TCS halobetasol propionate (HP, 0.01%) and TAZ (0.045%), indicated for the topical treatment of plaque psoriasis in adults, was developed to harness the therapeutic benefits of each active ingredient while minimizing their safety concerns.

METHODS:

This review describes data supporting the efficacy of halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) and remittive effect after treatment cessation in patients with hyperkeratotic plaques.

RESULTS:

Pivotal trials demonstrate the superior efficacy and safety of HP/TAZ over each active ingredient alone. Furthermore, we summarize a recent clinical study, which showed that HP/TAZ reduces lesional levels of tumor necrosis factor alpha and interleukin 17A, critical proinflammatory cytokines involved in keratinocyte hyperproliferation and psoriasis pathogenesis.

CONCLUSION:

This review suggests that HP/TAZ is a valuable option for the topical treatment of severe hyperkeratotic plaques through its additive mechanisms targeting inflammation and keratinocyte regulation.

2025-08-01·Journal of Drugs in Dermatology

Halobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance

Article

作者: Draelos, Zoe ; Jacobson, Abby

Scalp involvement in plaque psoriasis is accompanied by itching and scaling that reduce quality of life and exacerbate psoriatic-associated hair loss. Challenges for the topical treatment of scalp psoriasis include messy formulations that reduce patient adherence and dermal penetration in hair-bearing areas. This open-label study evaluated the efficacy of fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ, indicated for the topical treatment of plaque psoriasis in adults) in subjects with moderate-to-severe scalp psoriasis. Subjects applied HP/TAZ to the scalp once daily for 12 weeks and were evaluated at 4-week intervals. Endpoints included subject-reported scalp itch, investigator-reported psoriasis scalp severity index (PSSI), and investigator- and subject-reported hair and scalp assessments. From baseline, subjects experienced significant reductions in scalp itch and PSSI by week 12 (-49% and -93%, respectively; P≤0.001). Similarly, ratings for all investigator- and subject-assessed hair and scalp parameters were significantly improved from baseline at week 12 (P≤0.002 for all). No adverse events were reported. HP/TAZ is an efficacious treatment for scalp psoriasis, and reductions in psoriatic disease and itch may reduce scratching, leading to improvements in hair and scalp health.

2025-06-01·CLINICAL THERAPEUTICS

A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis

Article

作者: Lynde, C ; Hong, Hc-H ; Legault, M ; Barakat, M ; Vender, R ; Prajapati, V ; Zeinab, R

BACKGROUND:

A fixed-dose combination of HP/TAZ has demonstrated efficacy with a favorable safety profile for treating moderate-to-severe plaque psoriasis.

OBJECTIVE:

The present single-arm, open-label study evaluated the use of HP/TAZ in real-world practice.

METHODS:

Adults with moderate-to-severe psoriasis were enrolled and treated with HP/TAZ according to the Canadian label. The primary endpoint was the percentage of patients with treatment success at week 8, defined as an Investigator's Global Assessment score of clear or almost clear with a minimum 2-grade improvement.

RESULTS:

202 patients received at least one dose of HP/TAZ, 138 patients had efficacy assessments at baseline and week 8. Treatment success was achieved by 26.1% and 43.5% of patients (week 4 and 8 respectively) . Patient-rated average and worst itch were 4.5 and 5.3 points at baseline, with a subsequent reduction to 1.7 and 2.1 points, respectively, at week 8. Patients were satisfied-very satisfied with the HP/TAZ. Application site reactions (13.4%) and dermatitis/eczema (3.5%) were the most frequently reported adverse events (mild-moderate in severity) .

LIMITATIONS:

The study design may limit generalizability of the results as an open label real world evidence study lacking a placebo or comparator arm.

CONCLUSION:

Results confirm that HP/TAZ can be beneficial moderate-to-severe psoriasis patients.

项与丙酸乌倍他索相关的新闻（医药）

2025-08-21

·ir.bauschhealth.com

Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan

Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan (English) LAVAL, QC, August 21, 2025 – Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Quebec and Saskatchewan. This new public drug plan availability of CABTREO is in addition to that announced last month for those using the Ontario and Nova Scotia public drug plans as well as through the federal government’s Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations as well as those of the Correctional Service of Canada (CSC) and Veterans Affairs Canada. CABTREO is a new Canadian-made triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older. CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action – an antibiotic, a retinoid and an antibacterial agent – to provide a safe and effective treatment.1 “The addition of CABTREO to the Quebec and Saskatchewan public drug plans means more Canadians now have access to this innovative acne treatment – joining those already covered under most private insurance plans,” said Amy Cairns, General Manager, Bausch Health Canada. “Acne can have a significant impact on those living with it, and there is strong demand for new treatment options, increasing the importance of public drug plan coverage.” CABTREO, a prescription product, is a topical gel that is administered once daily to affected areas of the skin. Its active ingredients are the antibiotic clindamycin phosphate, the topical retinoid adapalene and the oxidizing agent benzoyl peroxide with a broad-spectrum bactericidal activity.1 About Acne Vulgaris Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population, including about 90 per cent of adolescents. About 25 per cent of teens will still have acne at age 25. Acne causes emotional distress and can cause permanent scarring.2 It can also cause skin pigmentation changes.3 CABTREO Clinical Data and Safety Information CABTREO was studied in two phase 3 multicentre, randomized, placebo controlled clinical trials in 363 patients with facial acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count, and percentage of patients achieving pre-defined treatment success. Combined efficacy results for both trials for CABTREO achieved approximately 50% treatment success and a greater than 70% reduction in both inflammatory and noninflammatory lesions at Week 12.1 The most frequent adverse reactions that may occur with CABTREO are mild to moderate application site reactions, such as skin irritation characterized by scaling, dryness, erythema, and burning/stinging. CABTREO should not be used by those who are hypersensitive to any of the ingredients in it (clindamycin phosphate, adapalene, benzoyl peroxide or to any ingredient in the formulation), patients with a history of regional enteritis (Crohn’s disease), ulcerative colitis or antibiotic-associated colitis or by pregnant women and women planning a pregnancy. CABTREO may bleach hair and coloured fabric so caution should be used when applying it near the hairline.1 Health Canada has not authorized CABTREO for pediatric use under the age of 12 years. CABTREO is for topical use only and is not for oral, ophthalmic or intravaginal use.1 About Dermatology at Bausch Health, Canada Inc. Bausch Health, Canada Inc. has one of the largest prescription dermatology businesses in Canada dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Bausch Health, Canada Inc. dermatology portfolio includes several leading acne, psoriasis, anti-fungal and corticosteroid-responsive dermatoses products. CABTREO is the fourth new dermatology treatment from Bausch Health, Canada Inc. approved by Health Canada and made available to Canadians over the past four years, adding to the company's leading portfolio in this important treatment area. The other approvals were for ARAZLOTM (tazarotene lotion, 0.045% w/w), for the topical treatment of acne vulgaris in patients 10 years of age and older; BRYHALI™ (halobetasol propionate lotion 0.01% w/w), for corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis in adults; and DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) to treat adults with moderate to severe plaque psoriasis.4 All four treatments – CABTREO, ARAZLO, BRYHALI and DUOBRII – are manufactured at Bausch Health's Laval, Quebec, facility for Canada and the United States. About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words “will,” “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “subject to” and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. REFERENCES 1 Bausch Health, Canada Inc., CABTREO Product Monograph,https://pdf.hres.ca/dpd_pm/00076715.PDF. 2 Canadian Dermatology Association, Acne, Quick Facts,https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%205.6%20million%20Canadians,adults%20ages%2020%20to%2040, accessed Aug. 20, 2024. 3 "What to Know about Hyperpigmentation Acne." Medical News Today, Jessica Caporuscio, April 28, 2021, https://www.medicalnewstoday.com/articles/hyperpigmentation-acne, accessed Aug. 20, 2024. 4 Bausch Health, Canada Inc., Canadian Product List, https://bauschhealth.ca/products/canadian-product-list/.

临床结果临床3期上市批准

2025-07-09

·ir.bauschhealth.com

Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs

LAVAL, QC, July 9, 2025 – Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as through the federal government’s Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations and that of the Correctional Service of Canada (CSC). CABTREO is a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older. CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action – an antibiotic, a retinoid and an antibacterial agent – to provide a safe and effective treatment.1 "It is very encouraging for people with acne vulgaris who use the Ontario, Nova Scotia and federal drug plans to now have access to CABTREO along with those on most private drug insurance plans,” said Amy Cairns, General Manager, Bausch Health, Canada Inc. “We look forward to completing listing arrangements in the near future with other public drug plans across Canada.” "We are pleased that public drug plans are ensuring Canadians with acne have access to new treatments, recognizing the importance of making different options available," said Kathy Giangaspero, Executive Director of the Acne and Rosacea Society of Canada. “Acne can significantly impact a person’s mental and physical health, so this is a big win for the patient community.” CABTREO, a prescription product, is a topical gel that is administered once daily to affected areas of the skin. Its active ingredients are the antibiotic clindamycin phosphate, the topical retinoid adapalene and the oxidizing agent benzoyl peroxide with a broad-spectrum bactericidal activity.1 About Acne Vulgaris Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population, including about 90 per cent of adolescents. About 25 per cent of teens will still have acne at age 25. Acne causes emotional distress and can cause permanent scarring.2 It can also cause skin pigmentation changes.3 CABTREO Clinical Data and Safety Information CABTREO was studied in two phase 3 multicentre, randomized, placebo controlled clinical trials in 363 patients with facial acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count, and percentage of patients achieving pre-defined treatment success. Combined efficacy results for both trials for CABTREO achieved approximately 50% treatment success and a greater than 70% reduction in both inflammatory and noninflammatory lesions at Week 12.1 The most frequent adverse reactions that may occur with CABTREO are mild to moderate application site reactions, such as skin irritation characterized by scaling, dryness, erythema, and burning/stinging. CABTREO should not be used by those who are hypersensitive to any of the ingredients in it (clindamycin phosphate, adapalene, benzoyl peroxide or to any ingredient in the formulation), patients with a history of regional enteritis (Crohn’s disease), ulcerative colitis or antibiotic-associated colitis or by pregnant women and women planning a pregnancy. CABTREO may bleach hair and coloured fabric so caution should be used when applying it near the hairline.1 Health Canada has not authorized CABTREO for pediatric use under the age of 12 years. CABTREO is for topical use only and is not for oral, ophthalmic or intravaginal use.1 About Dermatology at Bausch Health, Canada Inc. Bausch Health, Canada Inc. has one of the largest prescription dermatology businesses in Canada dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Bausch Health, Canada Inc. dermatology portfolio includes several leading acne, psoriasis, anti-fungal and corticosteroid-responsive dermatoses products. CABTREO is the fourth new dermatology treatment from Bausch Health, Canada Inc. approved by Health Canada and made available to Canadians over the past four years, adding to the company's leading portfolio in this important treatment area. The other approvals were for ARAZLO™ (tazarotene lotion, 0.045% w/w), for the topical treatment of acne vulgaris in patients 10 years of age and older; BRYHALI™ (halobetasol propionate lotion 0.01% w/w), for corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis in adults; and DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) to treat adults with moderate to severe plaque psoriasis.4 All four treatments – CABTREO, ARAZLO, BRYHALI and DUOBRII – are manufactured at Bausch Health's Laval, Quebec, facility for Canada and the United States. About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words “will,” “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “subject to” and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. REFERENCES 1 Bausch Health, Canada Inc., CABTREO Product Monograph, https://pdf.hres.ca/dpd_pm/00076715.PDF. 2 Canadian Dermatology Association, Acne, Quick Facts, https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%205.6%20million%20Canadians,adults%20ages%2020%20to%2040, accessed Aug. 20, 2024. 3 "What to Know about Hyperpigmentation Acne." Medical News Today, Jessica Caporuscio, April 28, 2021, https://www.medicalnewstoday.com/articles/hyperpigmentation-acne, accessed Aug. 20, 2024. 4 Bausch Health, Canada Inc., Canadian Product List, https://bauschhealth.ca/products/canadian-product-list/.

临床结果临床3期上市批准

2024-03-14

·PRNewswire

Psoriasis in America - Insights into Psoriasis Patient Demographics, Quality of Life, Information-seeking Behaviors, HCP Engagement and Treatment Experiences

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Psoriasis in America 2023: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. Approximately 7.5 million people in the United States have psoriasis. This Psoriasis in America report provides a comprehensive look at life for those living with psoriasis. Using detailed quantitative data, it gives a full picture of the psoriasis patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges. The report offers an in-depth look at the psoriasis patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the psoriasis patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more. This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs. This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information. The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S. This report includes a deep-dive into: Psoriasis patient demographics Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions Impact of psoriasis on quality of life Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood Information-seeking behaviors Information sources used, plus topics of interest HCP engagement Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used Psoriasis treatment awareness and experiences Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials Key questions answered in this report: To what extent do people say psoriasis impacts their overall quality of life? What's the average number of flares in the past year? What do patients wish others understood about psoriasis? What percentage of patients see a specialist for psoriasis treatment? What treatments have the highest aided brand awareness among patients? What percentage of patients use a biologic? How many patients feel their psoriasis is well-controlled on their current treatment plan? What percentage of patients are likely to switch or add new treatments in the next six months? What medications have patients discussed with their HCP? What are the top online resources people with psoriasis use to find information? What kinds of content and information do patients search for? What percentage of patients search for information on treatment options? Methodology Psoriasis in America consists of: A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions Qualitative patient insights from open-ended responses Additional details: Fielded: January 16, 2023 to April 14, 2023 Convenience sample of 490 respondents diagnosed with psoriasis Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners Key Topics Covered: Respondent Demographics Research Highlights Condition Status and Quality of Life Severity and Exacerbations Symptoms Experienced Impact on Quality of Life Qualitative Patient Insights Information-Seeking Behaviors Resources Used to Manage Health Types of Content/Information Sought Treatment Awareness and Experiences Primary HCP Seen for Psoriasis Care Aided Brand Awareness of Treatments Treatment Usage Condition Control on Current Treatment and Clinical Trial Interest Treatment Discussions with HCP Appendix with All Data Charts and Distributions Brands and treatments mentioned in this report include: Topical corticosteroid (such as hydrocortisone) BRYHALIT (halobetasol propionate) lotion DesOwen (desonide) SERNIVOT (betamethasone dipropionate) SORILUXT Foam (calcipotriene) TACLONEX (calcipotriene and betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) ZITHRANOLT-RR (anthralin) ZORYVET (roflumilast) Acitretin (SORIATANE) ARAVA (leflunomide) Azathioprine (such as IMURAN, AZASAN) Cyclosporine (such as Sandimmune, NEORAL, RESTASIS) Methotrexate (eg, Rheumatrex), also sometimes given as an injection OTEZLA (apremilast) PLAQUENIL (hydroxychloroquine) RINVOQ (upadacitinib) SOTYKTUT (deucravacitinib) Sulfasalazine (Azulfidine) XELJANZ/XELJANZ XR (tofacitinib citrate) AMJEVITAT (adalimumab-atto) Hide until launched in US AVSOLA (infliximab-axxq) CIMZIA (certolizumab) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) Hide until launched in US ENBREL (etanercept) ERELZIT (etanercept-szzs) Hide until launched in US HULIO (adalimumab-fkjp) Hide until launched in US HUMIRA (adalimumab) HYRIMOZ (adalimumab-adaz) Hide until launched in US ILUMYAT (tildrakizumab-asmn) INFLECTRA (infliximab-dyyb) IXIFIT (infliximab-qbtx) Hide until launched in US ORENCIA (abatacept) REMICADE (infliximab) RENFLEXIST (infliximab-abda) SIMPONI (golimumab) SIMPONI ARIA (golimumab for infusion) SILIQT (brodalumab) SKYRIZI (risankizumab-rzaa) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与丙酸乌倍他索相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04409	丙酸乌倍他索	D07AC21	DB00596

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
斑块状银屑病	美国	Lacerta Therapeutics, Inc.	2015-11-06
皮肤疾病	美国	Sun Pharmaceutical Industries, Inc.	1990-12-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
中度特应性皮炎	临床2期	美国	Sun Pharmaceutical Industries Ltd.	2017-07-24
重度特应性皮炎	临床2期	美国	Sun Pharmaceutical Industries Ltd.	2017-07-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAD2024	临床3期	斑块状银屑病	375	Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion	範獵願蓋餘獵網鑰憲齋(廠憲繭廠鹹觸範顧鬱壓): P-Value = ≤0.003 更多	积极	2024-03-08
				Vehicle Lotion
NCT03992261 (CTgov)	临床4期	斑块状银屑病	24	Halobetasol Topical Foam	顧艱鹽願壓膚齋築獵糧 = 獵夢淵糧願艱獵齋遞廠鏇獵築窪艱醖顧淵醖糧 (餘鑰鑰醖壓夢構網襯鏇, 夢壓糧製積齋網淵積簾 ~ 鑰廠鏇齋觸鏇艱夢蓋廠) 更多	-	2023-07-06
NCT03212963 (CTgov)	临床4期	斑块状银屑病	16	Halobetasol Topical Lotion	積憲憲顧網蓋艱網窪鹽 = 壓鑰襯鹽製簾鏇鑰獵願艱憲膚鏇網鹹淵鏇願鹹 (鹹築選艱鬱選鏇膚鑰淵, 襯選憲築窪觸蓋繭鹽顧 ~ 選壓壓糧獵衊齋範鏇築) 更多	-	2021-12-07
NCT02785185 (CTgov)	临床2期	斑块状银屑病	150	IDP-122 Lotion (IDP-122 Lotion)	網遞顧繭廠襯鑰簾鏇齋 = 鏇廠廠鑰範糧膚網艱衊糧衊蓋鹹齋鹹衊糧顧遞 (衊製遞範顧顧壓繭鬱窪, 鏇選製襯製夢築獵廠鹽 ~ 顧鏇簾鏇壓製餘鬱願繭) 更多	-	2020-08-27
				Ultravate Cream (Ultravate Cream)	網遞顧繭廠襯鑰簾鏇齋 = 膚蓋範鏇製築積觸餘獵糧衊蓋鹹齋鹹衊糧顧遞 (衊製遞範顧顧壓繭鬱窪, 窪鏇蓋夢繭築壓鹽築餘 ~ 膚糧醖蓋夢獵壓窪膚範) 更多
NCT02515097 (CTgov)	临床3期	斑块状银屑病	213	IDP-122 Lotion (IDP-122 Lotion)	簾醖觸獵齋艱鹹繭觸齋 = 築範壓衊膚壓範齋淵醖膚鏇衊艱網廠遞構廠襯 (鹽膚鏇製網蓋餘齋艱餘, 顧壓鹽獵網齋膚餘繭鹽 ~ 餘齋製餘積積窪鑰艱膚) 更多	-	2020-01-27
				IDP-122 (IDP-122 Vehicle Lotion)	簾醖觸獵齋艱鹹繭觸齋 = 糧淵觸製網艱餘餘壓醖膚鏇衊艱網廠遞構廠襯 (鹽膚鏇製網蓋餘齋艱餘, 繭醖艱構艱壓餘範遞廠 ~ 夢範糧鬱鹽憲範選繭製) 更多
NCT02514577 (CTgov)	临床3期	斑块状银屑病	217	IDP-122 Lotion (IDP-122 Lotion)	範積簾鏇膚餘窪蓋鹹醖 = 鹹構窪選衊簾網築憲醖艱選製艱壓衊願構蓋選 (壓憲鏇淵淵膚糧夢窪構, 製蓋艱廠糧鬱衊齋餘壓 ~ 顧積艱鬱獵鹽鹽鬱鑰築) 更多	-	2020-01-27
				IDP-122 (IDP-122 Vehicle Lotion)	範積簾鏇膚餘窪蓋鹹醖 = 憲選餘積鏇壓膚繭構糧艱選製艱壓衊願構蓋選 (壓憲鏇淵淵膚糧夢窪構, 願選觸廠網鬱簾鏇繭餘 ~ 選範鏇選獵獵觸選淵糧) 更多
NCT02785185 (Pubmed \| J Dermatolog Treat)	临床2期	斑块状银屑病	150	Halobetasol propionate 0.01% lotion	鑰餘廠衊窪醖遞艱觸壓(簾範餘壓鬱衊夢簾積糧) = 範繭鹹鑰築壓餘鹹醖製夢餘膚窪網壓願艱憲選 (壓範鬱夢獵廠築築淵網 ) 更多	-	2019-06-01
				Halobetasol propionate 0.05% cream	鑰餘廠衊窪醖遞艱觸壓(簾範餘壓鬱衊夢簾積糧) = 夢襯願糧壓遞糧觸繭製夢餘膚窪網壓願艱憲選 (壓範鬱夢獵廠築築淵網 ) 更多
NCT02368210 (CTgov)	临床3期	斑块状银屑病	151	122-0551 Foam (122-0551 Foam)	憲製夢醖遞獵醖淵範簾 = 壓襯簾淵糧鹹淵選廠壓夢醖鹽憲鬱夢鏇醖鹹鹹 (顧餘構憲艱獵網簾餘繭, 願窪顧鏇製願選衊鏇築 ~ 選範觸鹹繭鏇衊膚觸淵) 更多	-	2018-11-26
				Vehicle Foam (Vehicle Foam)	憲製夢醖遞獵醖淵範簾 = 壓齋餘鹹鑰艱鏇蓋網膚夢醖鹽憲鬱夢鏇醖鹹鹹 (顧餘構憲艱獵網簾餘繭, 製遞襯願範構夢鏇獵餘 ~ 網膚選網築夢淵網餘遞) 更多
NCT02742441 (CTgov)	临床3期	斑块状银屑病	409	122-0551 Foam (122-0551 Foam)	壓醖積築顧夢齋製鏇鹹 = 鬱蓋顧繭網顧壓製糧廠膚蓋淵齋窪蓋艱構顧餘 (夢艱選願齋蓋蓋夢壓壓, 築壓鑰襯製艱選遞衊鏇 ~ 簾鑰選憲顧艱遞顧鑰壓) 更多	-	2018-11-14
				Vehicle Foam (Vehicle Foam)	壓醖積築顧夢齋製鏇鹹 = 齋獵醖衊糧艱築夢範齋膚蓋淵齋窪蓋艱構顧餘 (夢艱選願齋蓋蓋夢壓壓, 繭製鹹壓憲範壓遞繭衊 ~ 襯積廠淵觸鑰壓膚餘壓) 更多
NCT02515097 (Pubmed) 人工标引	临床3期	斑块状银屑病	430	Halobetasol Propionate (Study 1)	獵膚襯鬱壓範製鬱築廠(築衊糧顧觸醖壓構窪壓) = 積蓋廠鹹廠窪簾衊壓網餘艱膚襯鹹顧醖艱鬱鏇 (鑰醖積選積廠顧鹽鹽鬱 )	积极	2018-10-01
				Halobetasol Propionate (Study 2)	獵膚襯鬱壓範製鬱築廠(築衊糧顧觸醖壓構窪壓) = 窪顧蓋觸壓觸鹹壓築選餘艱膚襯鹹顧醖艱鬱鏇 (鑰醖積選積廠顧鹽鹽鬱 )